Crispr Therapeutics AG (CRSP) — Long-term Investment Intensity
Crispr Therapeutics AG (CRSP) has a Long-term Investment Intensity of 1.3% as of September 2025. Long-term investments of $28.41 Million represent 1.3% of total assets of $2.25 Billion. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check Crispr Therapeutics AG cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Crispr Therapeutics AG Long-term Investment Intensity (2022–2023)
This chart shows how Crispr Therapeutics AG's Long-term Investment Intensity has evolved across 2 annual periods from 2022 to 2023. As of September 2025, the intensity stands at 1.3%, reflecting long-term investments of $28.41 Million against total assets of $2.25 Billion USD. Explore Crispr Therapeutics AG (CRSP) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Annual Long-term Investment Intensity for Crispr Therapeutics AG (2022–2023)
The table below presents the year-by-year Long-term Investment Intensity for Crispr Therapeutics AG from 2022 to 2023, covering 2 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see CRSP market cap.
| Year | LT Investment Intensity | LT Investments (USD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2023 | 0.1% | $1.97 Million | $2.23 Billion | ▼ -2.3 pp |
| 2022 | 2.4% | $53.13 Million | $2.24 Billion | — |